Table 1: Univariate analysis of the demographics and baseline characteristics of 241 RA patients.
|
Achieved SDAI 50 |
Did not achieve SDAI 50 |
P |
(Group A) |
(Group B) |
n |
139 |
102 |
|
Age (years) |
60 (43-68) |
57 (46-68) |
0.946* |
Sex (female, %) |
82 |
85 |
0.616** |
Disease duration (year) |
4 (2-9) |
4 (1-11) |
0.370* |
Smoking history (yes, %) |
22 |
35 |
0.038** |
Body mass index |
21 (20-24) |
21 (19-24) |
0.537* |
Biological agent (naïve, %) |
78 |
68 |
0.083** |
Steroid dosage (mg/d) |
2 (0-5) |
2 (0-5) |
0.905* |
MTX dosage (mg/w) |
8 (6-10) |
8 (6-12) |
0.105* |
Combined csDAMRDs (yes, %) |
17 |
16 |
0.880** |
ESR (mm/H) |
38 (16-67) |
21 (12-51) |
0.008* |
CRP (mg/dL) |
1 (0.29-3.74) |
1 (0.143-2.643) |
0.053* |
RF (mg/dL) |
64 (18.825-197.95) n=134 |
56 '26.35-135.15) n=99 |
0.381* |
MMP-3 (ng/mL) |
150 (74.9-312.4) n=132 |
140 (64-309) n=100 |
0.979* |
TJC |
7 (4-11) |
6 (2.25-10) |
0.178* |
SJC |
4 (2-8) |
3 (1-6) |
0.038* |
PTGA |
53 (31-74.5) |
55 (28-70.75) |
0.519* |
PHGA |
65 (32-76) |
48 (22.25-72) |
0.020* |
SDAI |
26 (17-35) |
18 (11-28) n=126 |
0.006* |
HAQ-DI |
0 (0.125-1) n=137 |
1 (0.09375-1.125) n=96 |
0.281* |
SF-36 |
PCS |
30 (21-39) n=103 |
30 (21-40) n=80 |
0.682* |
MCS |
50 (44-54) n=103 |
49 (44-55) n=80 |
0.791* |
RCS |
45 (31-56) n=103 |
45 (32-57) n=80 |
0.824* |
MTX, methotrexate
csDMARD, conventional synthetic disease-modifying antirheumatic drugs
RF, rheumatoid factor
MMP-3, matrix metalloproteinase 3
SDAI, simplified disease activity index
TJC, tender joint count
SJC, swollen joint count
PTGA, patient’s global assessment
PHGA, evaluator's global assessment
HAQ-DI, health assessment questionnaire disability index
SF-36, short form-36.
PCS, physical component summary score
MCS, mental component summary score
RCS, role/social component summary score
*analysis using MannWhitney U test
**analysis using chi-squared test for independence